CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1887 No intervention Wiki 0.24

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D000163 Acquired Immunodeficiency Syndrome NIH 0.58
D015658 HIV Infections NIH 0.32

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study

Healthcare workers in Wisconsin caring for critically ill COVID-19 patients will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, and thus reducing the incidence of COVID-19 in these healthcare workers.

NCT04478019 COVID-19 SARS-CoV 2 Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse

Primary Outcomes

Description: Participants will be monitored for positive COVID-19 test results during this trial

Measure: Number of Participants with COVID-19 diagnosis

Time: 8 weeks

Description: Viral load will be measured as a continuous outcome for each participant (three times per week) throughout this trial.

Measure: SARS-Cov-2 Viral Load

Time: 8 weeks

Secondary Outcomes

Description: Assessment of fidelity (as measured by percentage of compliance) to the treatment regimen will be measured by participants' reporting of intervention doses take through a daily treatment diary.

Measure: Fidelity of the treatment regimen

Time: 8 weeks

Description: A survey asking subjects to rank several factors that contribute to overall feasibility of use will be given pre- and post-intervention treatment.

Measure: Feasibility of the treatment regimen

Time: 2 weeks total: 1 week (pre-intervention) and 1 week after completion of intervention (post-intervention)

No related HPO nodes (Using clinical trials)